1 / 22

Program outline

Program outline. This program highlights the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial—providing an overview of ACE inhibition in patients with preserved left ventricular function, including the following topics: • The RAAS and its role in atherosclerosis

waite
Download Presentation

Program outline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Program outline • This program highlights the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial—providing an overview of ACE inhibition in patients with preserved left ventricular function, including the following topics: • • The RAAS and its role in atherosclerosis • • The role of ACE inhibition in CV risk reduction • • Update on recent trial data • • ACC/AHA recommendations of the role of ACE inhibition in post-MI patients

  2. Deleterious effects of angiotensin II PAI-1/thrombosis Ang II Abnormalvasoconstriction Plateletaggregation ActivateSNS Superoxideproduction Vascularsmooth musclegrowth Aldosterone Myocytegrowth Collagen Vasopressin Endothelin Remodeling Burnier M, Brunner HR. Lancet. 2000;355:637-45. Brown NJ, Vaughn DE. Adv Intern Med. 2000;45:419-29. SNS = Sympathetic nervous system

  3. PERTINENT: ACEI improves endothelial function—Effects on cultivated HUVECs Healthy control Perindopril 8 mg Placebo ecNOS activity (U/mg) Apoptosis (%) 9 4.0 P < 0.05 3.5 P < 0.05 7.8 8 3.5 3.3 7.0 6.8 7 2.9 3.0 6 2.5 2.4 2.5 5 4.7 2.0 4 1.5 3 1.0 2 1.3 1 0.5 0 0 Control Baseline 1 Year Control Baseline 1 Year HUVECs = human umbilical vein endothelial cells Ferrari R. ESC 2004; Munich.

  4. PERTINENT: Effects of ACEI on bradykinin, Ang II, and TNF — Plasma analysis Bradykinin Ang II 25 17.1 18 P < 0.05 15.8 P < 0.05 16 14.4 20 18.3 17.7 14 12.5 14.8 10.8 12 15 12.4 12.3 pg/mL pg/mL 10 8 10 6 4 5 2 0 0 Control Baseline 1 Year Control Baseline 1 Year 35 TNF- P < 0.05 28.9 30 27.7 27.1 24.6 25 Healthy control 20 18.0 pg/mL Perindopril 8 mg 15 Placebo 10 5 0 Ferrari R. ESC 2004; Munich. Control Baseline 1 Year

  5. Major clinical outcome trials of RAAS manipulation ACE inhibition GISSI-3 ISIS-4 AIRE SAVE SOLVD-Prevention TRACE CHARM-Preserved OPTIMAAL VALIANT Angiotensin receptor blockade HOPEEUROPA PEACE QUIET SOLVD-Treat CHARM-Added CHARM-Alternative ELITE II Val-HeFT ALLHAT ANBP2 INVEST LIFE CONSENSUS

  6. PEACE: Prevention of Events With Angiotensin Converting Enzyme Inhibition Objective: To assess the effect of ACE inhibition added to conventional therapy in patients with stable CAD and normal or slightly reduced LV function Design: 8290 patients randomized to trandolapril 4 mg or placebo Follow-up: 4.8 years Primary Outcome: CV death, nonfatal MI, CABG, PCI PEACE Trial Investigators. N Engl J Med. 2004;351:2058-68.

  7. PEACE: Treatment effect on primary outcome Placebo 30 25 Trandolapril 20 Incidence of primary outcome (%) 15 10 5 0 1 2 3 4 5 6 Years after randomization PEACE Trial Investigators. N Engl J Med. 2004;351:2058-68.

  8. PEACE: Treatment effect on components of primary outcome and total deaths *CV death, nonfatal MI, and coronary revascularization PEACE Trial Investigators. N Engl J Med. 2004;351:2058-68.

  9. HOPE, EUROPA: Overview HOPE Investigators. N Engl J Med. 2000;342:145-53. EUROPA Investigators. Lancet. 2003;362:782-8. *CV disease, peripheral artery disease, stroke or diabetes + ≥1 CV risk factor

  10. HOPE, EUROPA: Treatment benefit on primary and selected secondary outcomes Favors ACEI Favors placebo Event rate (%) ACEIPlacebo 14.0 17.8 8.0 9.9 6.1 8.1 3.5 4.1 9.9 12.3 4.8 6.2 3.4 4.9 1.6 1.7 0.8 1.3 0.1 0.2 Composite outcome CV mortality Myocardial infarction Stroke Cardiac arrest HOPE EUROPA 0.5 1.0 1.5 Hazard ratio EUROPA = European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease HOPE = Heart Outcomes Prevention Evaluation EUROPA Investigators. Lancet. 2003;362:782-8. HOPE Study Investigators. N Engl J Med. 2000;342:145-53.

  11. HOPE, EUROPA, PEACE, QUIET: CV event rate in placebo group 14 12.3 HOPE 12 EUROPA PEACE 10 QUIET 8.1 Event rate(%) 8 6.2 5.3 6 4.6 4.1 3.7 4 1.5 2 0 CV death Nonfatal MI HOPE Investigators. N Engl J Med. 2000;342:145-53. EUROPA Investigators. Lancet. 2003;362:782-8. PEACE Investigators. N Engl J Med. 2004;351:2058-68. Pitt B. et al. Am J Cardiol. 2001;87:1058-63.

  12. HOPE, EUROPA, PEACE, QUIET: CV therapies at baseline HOPE Investigators. N Engl J Med. 2000;342:145-53. EUROPA Investigators. Lancet. 2003;362:782-8. PEACE Investigators. N Engl J Med. 2004;351:2058-68. Pitt B. et al. Am J Cardiol. 2001;87:1058-63. *Mostly aspirin

  13. HOPE, EUROPA: Use of lipid-lowering drugs intensified during studies † Baseline During study 69 70 58 60 49* 50 % Patients 40 29 30 20 10 0 HOPE EUROPA *End of study †3 years Yusuf S. Symposium at: AHA 2004; New Orleans. EUROPA Investigators. Lancet. 2003;362:782-8.

  14. HOPE, EUROPA: Effect of ACEI plus concomitant CV therapy ACE inhibitor Added benefit No added benefit EUROPA* Lipid-lowering drug No lipid-lowering drug HOPE† Lipid-lowering drug No lipid-lowering drug EUROPA* -blockers No -blockers HOPE† -blockers No -blockers 0.6 0.8 1.0 2.0 *Perindopril 8 mg †Ramipril 10 mg EUROPA Investigators. Lancet. 2003;362:782-8 Dagenais GR et al. Circulation. 2001;104:522-6.

  15. HOPE: Dose-dependent effects of ramipril on LV mass and function Mean baseline LVEF 58% in all groups Placebo (n = 151) Ramipril 2.5 mg (n = 149) Ramipril 10 mg (n = 146) 10 6 5.31 5 8 8.21 7.86 ∆ LV end systolic volume (mL) 4 6 ∆ LV mass (g) 2.9 3 4 2 2 1 0 0 –2 –1 –2 –4 –3.53 –1.9 –3 –6 P Trend = 0.03 P Trend = 0.001 Lonn E et al. J Am Coll Cardiol. 2004;43:2200-6.

  16. SECURE: Dose-dependent effect of ramipril on carotid atherosclerosis 0.025 P= 0.028 0.022 NS 0.020 Slope of the mean maximum carotid-intima thickness (mm/y) 0.018 37% Reduction 0.015 0.014 0.010 0.005 0 Placebo Ramipril 2.5 mg Ramipril 10 mg Lonn E et al. Circulation. 2001;103:919-925.

  17. HOPE, EUROPA, PEACE, QUIET: Clinical implications • Cumulative evidence supports ACE inhibitors for a broad range of CAD patients • Not all ACE inhibitors can be assumed to have comparable effects on vascular protection • – Medication adherence and dosage are important • Evidence-based medicine should guide use • – Ramipril 10 mg (HOPE) • – Perindopril 8 mg (EUROPA) Pitt B. N Engl J Med. 2004;351:2115-7.

  18. 1-Year survival in post-MI patients according to ACEI Rx at discharge N = 7512 100 90 Cumulativesurvival*(%) Ramipril Perindopril Lisinopril 80 Enalapril Quinapril Fosinopril P < 0.001 for log-rank test Captopril 70 0 2 4 6 8 10 12 No. of patients Time (months) Ramipril 905 817 Perindopril 243 215 Lisinopril 2201 1894 Enalapril 2577 2118 Quinapril 276 224 Fosinopril 889 713 Captopril 421 325 *Unadjusted Pilote L et al. Ann Intern Med. 2004;141:102-12.

  19. 5-Year outcomes after PCI show major impact of disease progression 1228 patients in second-generation coronary stent trials Target-lesion event 25 Nontarget-lesion event Average event rate, years 2–5 20 6.7 7 18.3 Event rate (%) 15 5 12.4 % 10 3 7.0 6.7 5.8 5.7 1.7 5 2.3 1.5 1 1.6 1.3 0 Nontarget- lesion event Target-lesion event 1 2 3 4 5 Year Cutlip DE et al. Circulation. 2004;110:1226-30.

  20. APRES: Long-term benefit of ACEI started early after PTCA/CABG N = 159, ramipril 10 mg or placebo 1 to 7 days post-revascularization 25 APRES ends Cardiac death/HF 20 72% P = 0.018 at 4.3 yrs Placebo Event rate in cardiac death/HF (%) 15 Ramipril at 5.5 yrs 65% P = 0.042 10 5 at 6.9 yrs 35% P = 0.27 0 0 1 2 3 4 5 6 7 Years *APRES = Angiotensin-Converting Enzyme Inhibitor Post-Revascularization Study KjØller-Hansen L et al. Am Heart J. 2004;148:475-80.

  21. ACC/AHA recommendations on role of ACEIs in post-MI patients at discharge *Based on HOPE †Based on HOPE and EUROPA NSTEMI = non–ST-elevation MI STEMI = ST-elevation MI UA = unstable angina Braunwald E et al.www.acc.org/clinical/guidelines/unstable.pdf Antman EM et al. J Am Coll Cardiol. 2004;44:671-719.

  22. Cumulative impact of 4 CV-protective medication classes in post-MI patients • Cumulative risk reduction if all 4 medication classes are used: 70% • NNT to prevent 1 major CV event in 5 years: 7 RRR = relative risk reduction Fonarow GC. Rev Cardiovasc Med. 2003;4(suppl 3):537-46.

More Related